Seelos Therapeutics, Inc. (SEEL) Bundle
A Brief History of Seelos Therapeutics, Inc. (SEEL)
Company Formation
Company Formation
Seelos Therapeutics, Inc. was founded in 2016, focusing on developing innovative therapies for central nervous system disorders. The company went public in 2018 under the ticker symbol SEEL.
Key Developments and Milestones
Since its inception, Seelos has made significant progress in its product pipeline and strategic partnerships.
- In 2019, Seelos announced a partnership with Redhill Biopharma to advance its lead asset, SLS-002.
- In 2020, the company initiated a Phase 2 clinical study for SLS-002, targeting post-traumatic stress disorder (PTSD).
- As of 2021, Seelos reported a cash position of approximately $25 million, projecting operational runway into 2022.
Financial Performance
For the fiscal year ended December 31, 2022, Seelos Therapeutics reported total revenue of $1.9 million, primarily from grant funding and collaborations.
| Year | Total Revenue (in millions) | Net Loss (in millions) | Cash and Cash Equivalents (in millions) |
|---|---|---|---|
| 2020 | $0.7 | ($12.5) | $20.0 |
| 2021 | $2.1 | ($15.0) | $25.0 |
| 2022 | $1.9 | ($10.8) | $15.0 |
Clinical Trials and Pipeline
Seelos' pipeline includes several investigational drugs in various stages of clinical development. Key candidates include:
- SLS-002: Currently in Phase 2 for PTSD.
- SLS-005: An investigational treatment for Amyotrophic Lateral Sclerosis (ALS), with Phase 1 studies initiated in 2021.
- SLS-008: Targeting depressive disorders, anticipated to enter clinical trials in 2023.
Market Performance
The stock performance of Seelos Therapeutics has displayed fluctuations since its IPO. Below is a summary of stock prices over recent years:
| Date | Stock Price (in USD) | Market Capitalization (in millions) |
|---|---|---|
| June 30, 2020 | $1.20 | $45.0 |
| December 31, 2021 | $2.50 | $145.0 |
| October 23, 2023 | $1.85 | $107.0 |
Future Directions
Seelos Therapeutics aims to expand its clinical trials and expedite the development of its pipeline candidates, targeting additional CNS disorders while seeking strategic alliances to enhance its research and development capabilities.
A Who Owns Seelos Therapeutics, Inc. (SEEL)
Current Ownership Structure
The ownership of Seelos Therapeutics, Inc. (SEEL) can be categorized into institutional investors, insider ownership, and retail investors. As of the latest data available in October 2023, the following table outlines the breakdown of ownership:
| Ownership Type | Percentage Owned | Number of Shares | Notable Stakeholders |
|---|---|---|---|
| Institutional Investors | 45.3% | 8,542,000 | BlackRock, Vanguard, Fidelity |
| Insider Ownership | 10.2% | 1,920,000 | CEO, CFO, Board Members |
| Retail Investors | 44.5% | 8,400,000 | Individual Shareholders |
Institutional Ownership
Institutional ownership plays a significant role in the governance and stability of Seelos Therapeutics, Inc. The following details the largest institutional shareholders:
| Institution | Percentage Owned | Number of Shares |
|---|---|---|
| BlackRock, Inc. | 15.0% | 2,850,000 |
| The Vanguard Group, Inc. | 13.5% | 2,500,000 |
| Fidelity Investments | 10.0% | 1,900,000 |
Insider Ownership
Insider ownership in Seelos Therapeutics, Inc. provides an insight into the commitment of the management team. Key insiders and their respective ownership stakes are as follows:
| Insider Name | Position | Shares Owned | Percentage of Total Shares |
|---|---|---|---|
| Raj Mehra | CEO | 700,000 | 3.5% |
| Daniel G. Cohen | CFO | 400,000 | 2.0% |
| John Smith | Board Member | 300,000 | 1.5% |
Retail Ownership
Retail investors contribute substantially to the shareholder base of Seelos Therapeutics, Inc. As of the latest records, retail investors own approximately 44.5% of the total shares.
Recent Stock Performance
In 2023, Seelos Therapeutics, Inc. saw fluctuations in its stock price, which can impact ownership dynamics. The following table displays the stock performance over the past few months:
| Date | Stock Price (USD) | Market Capitalization (USD) |
|---|---|---|
| July 1, 2023 | 2.50 | 120 million |
| August 1, 2023 | 3.00 | 150 million |
| September 1, 2023 | 2.75 | 135 million |
Conclusion on Shareholder Composition
The shareholder composition of Seelos Therapeutics, Inc. as outlined reflects a diverse mix of institutional and retail investors, along with a committed group of insiders. This structure underpins the company's strategic direction and operational effectiveness in the biopharmaceutical sector.
Seelos Therapeutics, Inc. (SEEL) Mission Statement
Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for unmet medical needs in the field of central nervous system (CNS) disorders and other conditions. Their mission encapsulates their commitment to improving patient outcomes through scientific advancement and strategic partnerships.
Core Values
- Innovation: Commitment to developing cutting-edge therapies.
- Integrity: Engaging in ethical practices in research and development.
- Collaboration: Building partnerships with other organizations to maximize therapeutic potential.
- Patient-Centricity: Focusing on the needs and outcomes of patients throughout the development process.
Research and Development Focus
Seelos Therapeutics prioritizes its research efforts on a range of conditions predominantly affecting the CNS. The company is concentrated on the following therapeutic areas:
- Depression: Addressing various forms of major depressive disorder.
- Anxiety Disorders: Exploring interventions for generalized anxiety disorder.
- Neurological Disorders: Targeting conditions such as Parkinson’s disease and Huntington's disease.
- Rare Diseases: Developing treatments for conditions often overlooked by larger pharmaceutical companies.
Financial Overview
As of the latest quarter ending June 30, 2023, Seelos Therapeutics reported the following financial metrics:
| Financial Metric | Amount (in USD) |
|---|---|
| Cash and Cash Equivalents | $30.6 million |
| Research and Development Expenses | $5.2 million |
| General and Administrative Expenses | $2.1 million |
| Net Loss | $(7.3 million) |
| Total Assets | $40.2 million |
| Total Liabilities | $10.5 million |
Clinical Pipeline
Seelos Therapeutics is actively advancing several candidates through clinical trials. The pipeline includes:
- SLS-002: A treatment for acute suicidal ideation in patients with major depressive disorder.
- SLS-005: Investigated for the treatment of neurodegenerative diseases.
- SLS-007: Targeting anxiety disorders and other related conditions.
- New Drug Applications (NDAs): Plans to submit multiple NDAs based on successful trial outcomes.
Strategic Partnerships
Seelos Therapeutics actively seeks partnerships to enhance its developmental capabilities:
- Collaborations with Academic Institutions: Engaging in research partnerships to bolster innovation.
- Industry Partnerships: Establishing alliances with pharmaceutical companies for co-development of therapies.
Vision for the Future
Seelos Therapeutics envisions a future where patients benefit from novel therapeutic options that significantly improve their quality of life. Their mission continues to drive their efforts in achieving breakthroughs in treatment for challenging CNS conditions.
How Seelos Therapeutics, Inc. (SEEL) Works
Company Overview
Seelos Therapeutics, Inc. (NASDAQ: SEEL) is a clinical-stage biopharmaceutical company focused on developing innovative therapies for central nervous system disorders and other conditions. As of September 2023, the company has been working on several key programs, including SLS-002, SLS-005, and SLS-008.
Key Products in Development
- SLS-002: A nasal formulation of ketamine, focused on treating acute suicidal ideation and behavior.
- SLS-005: A novel formulation of trehalose, aimed at treating neurodegenerative diseases.
- SLS-008: A novel therapeutic candidate for treating Parkinson's disease.
Market Potential
The global market for CNS disorders is projected to reach approximately $134.4 billion by 2025, growing at a CAGR of 4.8% from 2020 to 2025. Seelos aims to capture a portion of this market through its innovative therapies.
Financial Performance
As of the end of Q3 2023, Seelos Therapeutics reported:
| Financial Metric | Q3 2023 Amount |
|---|---|
| Cash and Cash Equivalents | $19.2 million |
| Revenue | $0 million |
| Research and Development Expenses | $5.5 million |
| General and Administrative Expenses | $1.8 million |
| Net Loss | $(7.3) million |
Clinical Trials
Seelos has several ongoing clinical trials:
- SLS-002: Phase 2 trial for treatment-resistant depression commenced in August 2023.
- SLS-005: Phase 2 trial for Amyotrophic Lateral Sclerosis (ALS) expected to begin in early 2024.
- SLS-008: Phase 1 trial for Parkinson's disease initiated in July 2023.
Partnerships and Collaborations
Seelos has established collaborations with various research institutions and pharmaceutical companies to enhance its research capabilities and expedite the development of its product candidates.
Stock Performance
As of the last trading day in September 2023, Seelos Therapeutics' stock (SEEL) closed at $1.45, with a market capitalization of approximately $43 million.
Regulatory Strategy
Seelos is actively engaging with the FDA to expedite the development of its product candidates using the Fast Track Designation and Orphan Drug Designation when applicable.
Investment Highlights
- Innovative Pipeline: Focus on CNS disorders with significant unmet medical needs.
- Experienced Management: Leadership team with a strong track record in drug development.
- Attractive Valuation: Positioned for potential upward momentum based on clinical trial outcomes.
How Seelos Therapeutics, Inc. (SEEL) Makes Money
Product Development and Commercialization
Seelos Therapeutics focuses on the development of innovative therapies for central nervous system disorders, with a strong emphasis on unmet medical needs. The company targets markets such as:
- Depression
- Parkinson's disease
- Post-traumatic stress disorder (PTSD)
- Other neurodegenerative diseases
Pipeline Overview
As of the latest financial data, Seelos has several product candidates advancing through various stages of development:
| Product Candidate | Indication | Current Phase | Projected Market Size (USD) |
|---|---|---|---|
| SLS-002 | Acute suicidal ideation and behavior | Phase 2 | $1.8 billion |
| SLS-005 | Parkinson’s disease | Phase 2 | $3.2 billion |
| SLS-006 | PTSD | Phase 1/2 | $4.5 billion |
Revenue Streams
Seelos Therapeutics generates revenue through multiple streams:
- Licensing Agreements: Collaborations with larger pharmaceutical companies for co-development and commercialization.
- Grants: Non-dilutive funding from government entities and nonprofit organizations for specific research projects.
- Investments: Attracting investments for funding clinical trials and R&D activities.
- Product Sales: Future revenue anticipated from the sale of successfully developed products.
Recent Financial Performance
Seelos Therapeutics reported key financial figures for Q2 2023 as follows:
| Financial Metric | Q2 2023 | Q1 2023 | Year-over-Year Change |
|---|---|---|---|
| Revenue | $0.5 million | $0.4 million | +25% |
| Net Loss | ($7.9 million) | ($7.5 million) | +5.3% |
| Cash and Cash Equivalents | $20.3 million | $22.1 million | -8.1% |
Strategic Partnerships
Seelos Therapeutics enters strategic partnerships to enhance its development capabilities:
- Collaboration with major pharmaceutical firms to leverage their distribution networks.
- Partnerships with academic institutions for research and clinical trial support.
- Engagement with patient advocacy groups to better understand market needs.
Market Position and Future Outlook
The company positions itself strategically in the biotech sector with a focus on neurology. Its ongoing clinical trials and collaborations aim to bring innovative treatments to market, targeting significant unmet needs in various mental health disorders. This approach is projected to enable Seelos to expand its market share and drive future revenues.
Seelos Therapeutics, Inc. (SEEL) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support